Personalisierte Radioonkologie

Radiotherapy, either alone or in combination with surgery and/or chemotherapy is an important treatment modality for cancer patients. About 40-50% of cancer patients are treated with radiotherapy during the course of their disease. The radiosensitivity varies largely between tumor entities and even between patients bearing the same tumor type. Whereas most tumors are cured by a standard radiation treatment regimen (e.g. 30 fractions of 2 Gy), some tumors are resistant to these standard radiation doses due to intrinsic resistance mechanisms. However, a general increase of the radiation dose is not advisable because of the side effects caused by radiotherapy, which can severely affect the quality of life. Therefore, there is great interest in identifying biomarkers that can predict the radiosensitivity of a tumor. In the future, these biomarkers could be used as a basis for adjusting the appropriate radiation dose for individual patients. This personalized radiotherapy might improve the antitumor effect by simultaneously avoiding unnecessary side effects.

The aim of this project is the identification of innovative biomarkers in tumor tissues and/or blood that detect the individual differences in tumor radiosensitivity.



Development of Biomarkers. Source: Images were adopted from Servier Medical Art by Servier ( and modified under the following terms: Creative Commons Attribution 3.0 Unported (CC BY 3.0).